Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Spinal meningioma isa rare type of spinal cord cancer. The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic), and are typically slow growing. The initial signs and symptoms include headacheand recent onset of seizures. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). T he only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma. Surgery is the treatment of choice and complete tumor removal is reached in the vast majority of patients. The prognosis after surgical resection is excellent.
Biomarker and diagnostic research for spinal meningioma has been reported in the published literature.
No clinical trials have been registered for spinal meningioma.
75 publications have been identified in PubMed for spinal meningioma. Research spans Case Report / Case Series (47%), Clinical Trial Publication (23%), and Review / Meta-Analysis (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 35 | 47% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 10:17 AM UTC
Genetic and Rare Diseases Info Center
17 |
23% |
Research summaries | 7 | 9% |
Laboratory research | 7 | 9% |
Disease patterns and progression | 7 | 9% |
Testing and diagnosis research | 2 | 3% |
Ramponi A (2026). [PMID: 41903773](https://pubmed.ncbi.nlm.nih.gov/41903773/). *Neurochirurgie*. [Case Report / Case Series]
Nakamoto Y (2026). [PMID: 41983085](https://pubmed.ncbi.nlm.nih.gov/41983085/). *Case Rep Vet Med*. [Case Report / Case Series]
Uno A (2026). [PMID: 42014064](https://pubmed.ncbi.nlm.nih.gov/42014064/). *J Am Anim Hosp Assoc*. [Case Report / Case Series]
Yavuz AY (2026). [PMID: 42171735](https://pubmed.ncbi.nlm.nih.gov/42171735/). *Eur Spine J*. [Clinical Trial Publication]
Castillo Rangel C (2026). [PMID: 42158061](https://pubmed.ncbi.nlm.nih.gov/42158061/). *J Spine Surg*. [Case Report / Case Series]
Yuan F (2026). [PMID: 42191869](https://pubmed.ncbi.nlm.nih.gov/42191869/). *Eur Spine J*. [Case Report / Case Series]
Dave BR Sr (2026). [PMID: 42199587](https://pubmed.ncbi.nlm.nih.gov/42199587/). *Cureus*. [Clinical Trial Publication]
Iampreechakul P (2026). [PMID: 42232404](https://pubmed.ncbi.nlm.nih.gov/42232404/). *Surg Neurol Int*. [Case Report / Case Series]
Corliss LE (2026). [PMID: 41660310](https://pubmed.ncbi.nlm.nih.gov/41660310/). *Surgical neurology international*. [Case Report / Case Series]
Germano IM (2026). [PMID: 42221984](https://pubmed.ncbi.nlm.nih.gov/42221984/). *Neurooncol Adv*. [Review / Meta-Analysis]